



NATIONAL SCIENCE ADVISORY BOARD FOR BIOSECURITY

National Institutes of Health
9000 Rockville Pike
Bldg. 31, 6C, Room 10
Bethesda, MD



May 5, 2015

MEETING AGENDA

8:30 – 8:50 am Welcome and Introductions

8:30 – 8:35 am

Opening Remarks

Samuel L. Stanley, M.D.

Chair, NSABB

President, Stony Brook University

8:35 – 8:45 am

Introduction of NSABB Voting and *Ex Officio* Members

Christopher J. Viggiani, Ph.D.

Acting Executive Director, NSABB

Office of Science Policy, Office of the Director, National Institutes of Health

Review of Conflict of Interest Rules

Christopher J. Viggiani, Ph.D.

8:45 – 8:50 am

Approval of NSABB Meeting Minutes

Samuel L. Stanley, M.D.

8:50 – 9:20 am

Review of Gain-of-Function Deliberative Process and Charge to NSABB

Carrie D. Wolinetz, Ph.D.

Associate Director for Science Policy

National Institutes of Health

Questions from NSABB and Discussion

9:20 – 12:00 pm

Review & Discussion of NSABB Draft Framework for Conducting Risk and Benefit Assessments of Gain-of-Function Research

9:20 – 9:45 am

Update from the NSABB Working Group: A Draft Framework for Conducting Risk and Benefit Assessments on Gain-of-Function Studies Involving Pathogens with Pandemic Potential

Joseph Kanabrocki, Ph.D., C.B.S.P.

Co-chair, NSABB Working Group

Associate Vice President for Research Safety

Professor of Microbiology

University of Chicago

9:45 – 10:30 am	<p>NSABB Review & Discussion of the Draft Framework for Conducting Risk and Benefit Assessments on Gain-of-Function Research Kenneth I. Berns, M.D., Ph.D. <i>Co-chair, NSABB Working Group</i> <i>Distinguished Professor</i> <i>Dept. of Molecular Genetics & Microbiology</i> <i>Genetics Institute</i> <i>College of Medicine</i> <i>University of Florida</i></p> <p>Focused discussion to include:</p> <ul style="list-style-type: none"> • Pathogens and Pathogen Characteristics • Risk Categories • Benefit Categories • Scenarios • Biosafety Assumptions
10:30 – 10:45 am	Break
10:45 – 12:00 pm	<p>Continued Review & Discussion of NSABB Draft Framework for Conducting Risk and Benefit Assessments of Gain-of-Function Research Kenneth I. Berns, M.D., Ph.D. Joseph Kanabrocki, Ph.D., C.B.S.P.</p>
12:00 – 1:00 pm	Lunch
1:00 – 2:00 pm	<p>Overview of Conducting Risk and Benefit Assessments of Gain-of-Function Research Methods and Approaches to Conducting Risk and Benefit Assessments of Gain-of-Function Research Rocco Casagrande, Ph.D. <i>Managing Director, Gryphon Scientific</i></p> <p>Questions from NSABB and Discussion</p>
2:00 – 2:30 pm	Public Comment (Session I)
2:30 – 3:00 pm	<p>Additional Discussion of NSABB Draft Framework for Conducting Risk and Benefit Assessments of Gain-of-Function Research NSABB Discussion on Draft Framework; Vote to Approve if Appropriate Samuel L. Stanley, M.D.</p>
3:00 – 4:00 pm	<p>Addressing the NSABB’s Charge on Gain-of-Function Research: The Path Forward</p>
3:00 – 3:30 pm	<p>Discussion of Upcoming NSABB Deliberations: Identifying Information and Expertise to Develop Recommendations Susan Wolf, J.D. <i>Member, NSABB</i> <i>McKnight Presidential Professor of Law, Medicine & Public Policy</i> <i>Faegre Baker Daniels Professor of Law</i> <i>Professor of Medicine</i> <i>Faculty Member, Center for Bioethics</i></p>

University of Minnesota

Joseph McDade, Ph.D.

Member, NSABB

Deputy Director (Retired)

National Center for Infectious Diseases

Centers for Disease Control and Prevention

3:30 – 3:50 pm

Public Comment (Session II)

3:50 – 4:00 pm

Closing Remarks and Adjourn

Samuel L. Stanley, M.D.